Reaction

Bladder Spasm reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 1,836 reports · 48 co-occurring drugs

As of the last recalculation, Bladder Spasm appears in 1,836 FAERS reports alongside 48 co-occurring drug terms. The strongest observed disproportionality signal is FESOTERODINE FUMARATE (PRR 39.5).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Fesoterodine Fumarate	37	39.5	39.6
Vibegron	26	37.3	37.4
Tolterodine Tartrate	20	25.5	25.6
Mirabegron	82	25.1	25.2
Oxybutynin	59	23.6	23.6
Oxybutynin Chloride	17	22.2	22.2
Tizanidine Hydrochloride	19	12.0	12.0
Cimetidine	9	10.6	10.7
Nitrofurantoin	15	10.4	10.4
Nitrofurantoin (Monohydrate/Macrocrystals)	15	10.3	10.3
Amphotericin B	11	10.0	10.0
Zinc	20	9.3	9.3
Zinc Chloride	20	9.2	9.2
Zinc Gluconate	21	9.2	9.2
Ocrelizumab	47	8.8	8.8
Baclofen	62	8.4	8.4
Modafinil	23	8.2	8.2
Dicyclomine Hydrochloride	10	8.0	8.0
Calcium, Magnesium, Potassium, And Sodium Oxybates	6	7.9	7.9
Valganciclovir Hydrochloride Powder,	8	7.5	7.5
Heparin Sodium	9	7.5	7.5
Tamsulosin Hydrochloride	13	7.3	7.3
Relugolix	15	7.3	7.3
Lanreotide Acetate	5	7.2	7.3
Interferon Beta-1B	12	7.1	7.1
Ifosfamide	13	6.9	6.9
Dalfampridine	41	6.6	6.6
Onabotulinumtoxina	43	6.4	6.4
Lisinopril And Hydrochlorothiazide Tablets	4	5.8	5.8
Azelastine	9	5.7	5.7
Armodafinil	10	5.4	5.4
Irinotecan Hydrochloride	6	5.3	5.3
Siponimod	4	5.1	5.1
Sodium Oxybate	29	5.1	5.1
Niraparib	9	4.6	4.6
Botulinum Toxin Type A	5	4.6	4.6
Interferon Beta-1A	70	4.2	4.2
Natalizumab	65	4.2	4.2
Ofatumumab	12	4.1	4.1
Teriflunomide	16	4.0	4.0
Apalutamide	4	3.9	3.9
Avapritinib	4	3.8	3.8
Enzalutamide	18	3.5	3.5
Canagliflozin	8	3.0	3.0
Diroximel Fumarate	3	2.9	2.9
Esketamine Hydrochloride	4	2.5	2.5
Dimethyl Fumarate	24	2.2	2.2
Copper	4	1.1	1.1

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.